NEULAND LABORATORIES
Back to Balance Sheet
|
NEULAND LABORATORIES Last 5 Year Contingent Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Contingent Liabilities | ₹13 Cr | ₹8.97 Cr | ₹28 Cr | ₹91 Cr | ₹75 Cr |
What is the latest Contingent Liabilities ratio of NEULAND LABORATORIES ?
| Year | Contingent Liabilities |
|---|---|
| Mar2026 | ₹13 Cr |
| Mar2025 | ₹8.97 Cr |
| Mar2024 | ₹28 Cr |
| Mar2023 | ₹91 Cr |
| Mar2022 | ₹75 Cr |
How is Contingent Liabilities of NEULAND LABORATORIES Trending?
| Years | Contingent Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹13 Cr | 46.92 | |
| Mar2025 | ₹8.97 Cr | -67.65 | |
| Mar2024 | ₹28 Cr | -69.60 | |
| Mar2023 | ₹91 Cr | 22.14 | |
| Mar2022 | ₹75 Cr | - | |
Compare Contingent Liabilities of peers of NEULAND LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NEULAND LABORATORIES | ₹23,770.6 Cr | -2% | 2.8% | 27.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹465,711.0 Cr | -0.8% | 3.5% | 14.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹192,376.0 Cr | -1% | 7.3% | 7.6% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹188,655.0 Cr | -0.9% | 10.1% | 44.6% | Stock Analytics | |
| CIPLA | ₹113,979.0 Cr | -2.1% | -1.8% | -6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,204.7 Cr | -5.8% | -13.2% | -7.7% | Stock Analytics | |
NEULAND LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NEULAND LABORATORIES | -2% |
2.8% |
27.1% |
| SENSEX | -2.7% |
-0.2% |
-8% |
You may also like the below Video Courses